Some say the recent allegations about a potential stem cell breakthrough unveiled in January by a major Japanese research institution represent a larger problem of irreproducibility in early science research. But others, like Edward Ahn, managing director and chief science officer of Cambridge, MA-based MedCap Advisors, think we shouldn't jump to conclusions quite yet.
These alliances benefit not only pharma companies, which gain access to world-class scientists and robust drug discovery programs, but also academic institutions, which increasingly are realizing that relationships with Big Pharma are more and more vital.
At a time when most of the biopharma industry has focused its preclinical research on screening synthetic compounds for their drug potential, Biosortia Pharmaceuticals is going back to nature to find promising compounds at the early stage of discovery. Read more >>
Embryonic stem cell research has yet to live up to all the hype. So far, human embryonic stem cells, or hESCs, haven't yielded any cures or therapies to treat diseases. Read more >>
Inking big deals with pharma giants Bristol-Myers Squibb and AstraZeneca, Vanderbilt has emerged as a leading institution for central nervous system drug research and discovery by bringing a business-like approach to the lab.
Stem cell-based therapeutics are a fast-growing area of early-stage biotech research, but they need better production methods to enable large-scale R&D.
FierceBiotechResearch will be taking a brief break over the holidays, but we will be back Jan. 2.
As of today's issue, please welcome Suzanne Elvidge as the new editor for FierceBiotechResearch.
Here's a question: As the nation's leading, independent nonprofit life sciences research institutes pursue the quest for cures and answers to the major medical challenges of our time, how high a salary should be paid to the person in charge?
Check out the full top 20 list >>
At the long-awaited kickoff of the 2012 BIO International Convention in Boston June 18, many of the initial sessions weren't exactly crowded. The same can't be said, however, for the all-day session on China.